Anders Berglund, PhD

Dr. Berglund's research is focused on applying existing strategies and deriving new methods to analyze high-dimensional, complex data from various types of cancer-related experiments.

Associations

• Biostatistics and Bioinformatics
• Molecular Medicine Program

Education & Training

Graduate:

• Umea University Umea Sweden, PhD - Chemometrics/Organic Chemistry

Fellowship:

• Washington University St. Louis - Molecular Design

Anders E. Berglund, Ph.D., is currently an Associate Member at Moffitt Cancer Center in the Department of Biostatistics and Bioinformatics. Dr. Berglund's background is in computational chemistry, computational biology, and bioinformatics. Dr. Berglund has extensive experience in analyzing various molecular datasets to both answer specific questions related to cancer research and generate new hypotheses that can be tested in the lab. Dr. Berglund’s research has been focused on how to validate PCA-based gene signatures and, more recently, on how to best visualize and analyze methylation data. Dr. Berglund's work in methylation data includes validation of using FFPE tissue for DNA methylation and evaluating several DNA repair methods, new ways to visualize gene level methylation data, large pan-cancer studies of key immune genes, and leading the analysis of in-house methylation projects. Dr. Berglund has also collaborated with Moffitt investigators to develop a 12-chemokine signature, evaluating it across several tumor types and, most recently, making the 12-chemokine gene signature CLIA-approved. As a collaborative bioinformatic scientist, Dr. Berglund has collaborated with many Moffitt scientists and clinicians across many tumor types, for example, in Melanoma, Kidney, Ovarian, and Prostate cancer, leading to both first-author publications and even more publications as co-author. Dr. Berglund also has experience in immune-oncology and, more recently, in the discovery of how dysregulation of immune synapse genes leads to the modulation of tumor immunogenicity. Furthermore, Dr. Berglund has also shown the importance of silencing both STING and cGAS in both pan-cancer studies and in melanoma.

• Peak T, Tian Y, Patel A, Shaw T, Obermayer A, Laborde J, Kim Y, Johnson J, Stewart P, Fang B, Teer JK, Koomen J, Berglund A, Marchion D, Francis N, Echevarria PR, Dhillon J, Clark N, Chang A, Sexton W, Zemp L, Chahoud J, Wang L, Manley B. Pathogenic Roles for RNASET2 in Clear Cell Renal Cell Carcinoma. Lab Invest. 2024 Feb.104(5):102041. Pubmedid: 38431116.
• Dickey BL, Putney RM, Schell MJ, Berglund AE, Amelio AL, Caudell JJ, Chung CH, Giuliano AR. Identification of a Biomarker Panel from Genome-Wide Methylation to Detect Early HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila). 2024 Apr.17(4):169-176. Pubmedid: 38286404. Pmcid: PMC10987272.
• Wu Q, Berglund AE, Macaulay RJ, Etame AB. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status. Int J Mol Sci. 2023 Oct.24(20). Pubmedid: 37894860. Pmcid: PMC10606804.
• Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clin Cancer Res. 2023 Oct.29(19):3875-3881. Pubmedid: 37505486.
• Soupir AC, Hayes MT, Peak TC, Ospina O, Chakiryan NH, Berglund AE, Stewart PA, Nguyen J, Segura CM, Francis NL, Echevarria PMR, Chahoud J, Li R, Tsai KY, Balasi JA, Peres YC, Dhillon J, Martinez LA, Gloria WE, Schurman N, Kim S, Gregory M, Mulé J, Fridley BL, Manley BJ. Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment. bioRxiv. 2023 Nov. Pubmedid: 38014063. Pmcid: PMC10680839.
• Dickey BL, Putney RM, Suneja G, Kresovich JK, Spivak AM, Patel AB, Teng M, Extermann M, Giuliano AR, Gillis N, Berglund A, Coghill AE. Differences in epigenetic age by HIV status among patients with a non-AIDS defining cancer. Aids. 2023 Nov.37(13):2049-2057. Pubmedid: 37467055. Pmcid: PMC10538418.
• Falahat R, Berglund A, Perez-Villarroel P, Putney RM, Hamaidi I, Kim S, Pilon-Thomas S, Barber GN, Mulé JJ. Epigenetic state determines the in vivo efficacy of STING agonist therapy. Nat Commun. 2023 Mar.14(1):1573. Pubmedid: 36949064. Pmcid: PMC10033671.
• El-Kenawi A, Berglund A, Estrella V, Zhang Y, Liu M, Putney RM, Yoder S, Johnson J, Brown J, Gatenby R. Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells. Cancer Res. 2023 Mar.83(5):720-734. Pubmedid: 36480167. Pmcid: PMC9978888.
• Heine J, Fowler EEE, Berglund A, Schell MJ, Eschrich S. Techniques to produce and evaluate realistic multivariate synthetic data. Sci Rep. 2023 Jul.13(1):12266. Pubmedid: 37507387. Pmcid: PMC10382509.
• Nakanishi S, Li J, Berglund AE, Kim Y, Zhang Y, Zhang L, Yang C, Song J, Mirmira RG, Cleveland JL. The Polyamine-Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma. Blood Cancer Discov. 2023 Jul.4(4):294-317. Pubmedid: 37070973. Pmcid: PMC10320645.
• Burger KL, Fernandez MR, Meads MB, Sudalagunta PR, Oliveira PS, Renatino Canevarolo R, Alugubelli RR, Tungsevik A, De Avila G, Silva M, Graeter AI, Dai H, Vincelette ND, Prabhu A, Magaletti D, Yang C, Li W, Kulkarni A, Hampton OA, Koomen JM, Roush WR, Monastyrskyi A, Berglund AE, Silva AS, Cleveland JL, Shain KH. CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma. Cancer Res. 2023 Dec.83(23):3901-3919. Pubmedid: 37702657. Pmcid: PMC10690099.
• Ottman R, Ganapathy K, Lin HY, Osterman CD, Dutil J, Matta J, Ruiz-Deya G, Wang L, Yamoah K, Berglund A, Chakrabarti R, Park JY. Differential Expression of miRNAs Contributes to Tumor Aggressiveness and Racial Disparity in African American Men with Prostate Cancer. Cancers (Basel). 2023 Apr.15(8). Pubmedid: 37190259. Pmcid: PMC10136561.
• Chakiryan NH, Kim Y, Berglund A, Chang A, Kimmel GJ, Hajiran A, Nguyen J, Moran-Segura C, Saeed-Vafa D, Katende EN, Lopez-Blanco N, Chahoud J, Rappold P, Spiess PE, Fournier M, Jeong D, Wang L, Teer JK, Dhillon J, Kuo F, Hakimi AA, Altrock PM, Mulé JJ, Manley BJ. Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma. J Immunother Cancer. 2023 Apr.11(4). Pubmedid: 37185232. Pmcid: PMC10151991.
• Zota V, Siegal GP, Kelly D, Bridge JA, Berglund A, Bui K, Khalil F, R Reed D, Altiok S, Magliocco A, Bui MM. Validation of PRKCB Immunohistochemistry as a Biomarker for the Diagnosis of Ewing Sarcoma. Fetal Pediatr Pathol. 2023 Apr.42(2):241-252. Pubmedid: 36062956.
• Chhabra R, Guergues J, Wohlfahrt J, Rockfield S, Espinoza Gonzalez P, Rego S, Park MA, Berglund AE, Stevens SM, Nanjundan M. Deregulated expression of the 14q32 miRNA cluster in clear cell renal cancer cells. Front Oncol. 2023 Apr.13:1048419. Pubmedid: 37139155. Pmcid: PMC10150008.
• Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022 Sep.400(10357):1008-1019. Pubmedid: 36108657. Pmcid: PMC9533323.
• Hesterberg RS, Liu M, Elmarsafawi AG, Koomen JM, Welsh EA, Hesterberg SG, Ranatunga S, Yang C, Li W, Lawrence HR, Rodriguez PC, Berglund AE, Cleveland JL. TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate. Cancer Immunol Res. 2022 Oct.10(10):1263-1279. Pubmedid: 35969234. Pmcid: PMC9662872.
• Rappold PM, Vuong L, Leibold J, Chakiryan NH, Curry M, Kuo F, Sabio E, Jiang H, Nixon BG, Liu M, Berglund AE, Silagy AW, Mascareno A, Golkaram M, Marker M, Reising A, Savchenko A, Millholland JM, Chen YB, Russo P, Coleman J, Reznik E, Manley BJ, Ostrovnaya I, Makarov V, DiNatale RG, Blum KA, Ma X, Chowell D, Li MO, Solit DB, Lowe SW, Chan TA, Motzer RJ, Voss MH, Hakimi AA. A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2022 Oct.12(10):2308-2329. Pubmedid: 35758895. Pmcid: PMC9720541.
• Chang A, Chakiryan NH, Du D, Stewart PA, Zhang Y, Tian Y, Soupir AC, Bowers K, Fang B, Morganti A, Teer JK, Kim Y, Spiess PE, Chahoud J, Noble JD, Putney RM, Berglund AE, Robinson TJ, Koomen JM, Wang L, Manley BJ. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022 Oct.82(4):354-362. Pubmedid: 35718636.
• Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 May.8(3):784-793. Pubmedid: 33994165.
• Song X, Chang S, Seminario-Vidal L, de Mingo Pulido A, Tordesillas L, Song X, Reed RA, Harkins A, Whiddon S, Nguyen JV, Moran Segura C, Zhang C, Yoder S, Sayegh Z, Zhao Y, Messina JL, Harro CM, Zhang X, Conejo-Garcia JR, Berglund AE, Sokol L, Zhang J, Rodriguez PC, Mule JJ, Futreal AP, Tsai KY, Chen PL. Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discov. 2022 May.12(5):1294-1313. Pubmedid: 35247891. Pmcid: PMC9148441.
• Ferrall-Fairbanks MC, Chakiryan N, Chobrutskiy BI, Kim Y, Teer JK, Berglund A, Mulé JJ, Fournier M, Siegel EM, Dhillon J, Falasiri SSA, Arturo JF, Katende EN, Blanck G, Manley BJ, Altrock PM. Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Res. 2022 Mar.82(5):929-942. Pubmedid: 35031572. Pmcid: PMC8898280.
• Freischel AR, Teer JK, Luddy K, Cunningham J, Artzy-Randrup Y, Epstein T, Tsai KY, Berglund A, Cleveland JL, Gillies RJ, Brown JS, Gatenby RA. Evolutionary Analysis of TCGA Data Using Over- and Under- Mutated Genes Identify Key Molecular Pathways and Cellular Functions in Lung Cancer Subtypes. Cancers (Basel). 2022 Dec.15(1). Pubmedid: 36612014. Pmcid: PMC9817988.
• Fernandez MR, Schaub FX, Yang C, Li W, Yun S, Schaub SK, Dorsey FC, Liu M, Steeves MA, Ballabio A, Tzankov A, Chen Z, Koomen JM, Berglund AE, Cleveland JL. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Res. 2022 Apr.82(7):1234-1250. Pubmedid: 35149590. Pmcid: PMC9004540.
• Ospina OE, Wilson CM, Soupir AC, Berglund A, Smalley I, Tsai KY, Fridley B. spatialGE: quantification and visualization of the tumor microenvironment heterogeneity using spatial transcriptomics. Bioinformatics. 2022 Apr.38(9):2645-2647. Pubmedid: 35258565.
• Berglund A, Muenyi C, Siegel EM, Ajidahun A, Eschrich SA, Wong D, Hendrick LE, Putney RM, Kim S, Hayes DN, Shibata D. Characterization of Epigenomic Alterations in HPV16+ Head and Neck Squamous Cell Carcinomas. Cancer Epidemiol Biomarkers Prev. 2022 Apr.31(4):858-869. Pubmedid: 35064062. Pmcid: PMC8983563.
• Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 Apr.81(4):325-330. Pubmedid: 33303244.
• Berglund A, Putney RM, Hamaidi I, Kim S. Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. Exp Mol Med. 2021 May.53(5):761-771. Pubmedid: 33963293. Pmcid: PMC8178403.
• Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, Hitosugi T, Cheng CH, Freischel AR, Zhang L, Li W, Hou H, Schaub FX, Vedder AR, Cen L, McGraw KL, Moon J, Murphy DJ, Ballabio A, Kaufmann SH, Berglund AE, Cleveland JL. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discov. 2021 Mar.2(2):162-185. Pubmedid: 33860275. Pmcid: PMC8043621.
• Grove O, Berglund AE, Schabath MB, Aerts HJWL, Dekker A, Wang H, Velazquez ER, Lambin P, Gu Y, Balagurunathan Y, Eikman E, Gatenby RA, Eschrich S, Gillies RJ. Correction: Quantitative Computed Tomographic Descriptors Associate Tumor Shape Complexity and Intratumor Heterogeneity with Prognosis in Lung Adenocarcinoma. PLoS One. 2021 Mar.16(3):e0248541. Pubmedid: 33684181. Pmcid: PMC7939347.
• Li R, Berglund A, Zemp L, Dhillon J, Putney R, Kim Y, Jain RK, Grass GD, Conejo-Garcia J, Mulé JJ. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Front Immunol. 2021 Jun.12:694079. Pubmedid: 34267760. Pmcid: PMC8276102.
• Hernandez-Prera J, Valderrabano P, Creed J, de la Iglesia JV, Slebos R, Centeno BA, Tarasova V, Hallanger-Johnson J, Veloski C, Otto KJ, Wenig BM, Yoder S, Lam C, Park DS, Anderson AR, Raghunand N, Berglund A, Caudell J, Gerke TA, Chung CH. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2021 Jan.31(1):36-49. Pubmedid: 32689909. Pmcid: PMC7864115.
• Ruiz-Deya G, Matta J, Encarnación-Medina J, Ortiz-Sanchéz C, Dutil J, Putney R, Berglund A, Dhillon J, Kim Y, Park JY. Differential DNA Methylation in Prostate Tumors from Puerto Rican Men. Int J Mol Sci. 2021 Jan.22(2). Pubmedid: 33450964. Pmcid: PMC7828429.
• Awasthi S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, Kensler KH, Serna AN, Vidal AC, You S, Freeman MR, Davicioni E, Liu Y, Karnes JR, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk SP, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 Jan.27(1):320-329. Pubmedid: 33037017. Pmcid: PMC8042600.
• Lin HY, Wang X, Tseng TS, Kao YH, Fang Z, Molina PE, Cheng CH, Berglund AE, Eeles RA, Muir KR, Pashayan N, Haiman CA, Brenner H, Consortium TP, Park JY. Alcohol Intake and Alcohol-SNP Interactions Associated with Prostate Cancer Aggressiveness. J Clin Med. 2021 Feb.10(3). Pubmedid: 33540941. Pmcid: PMC7867322.
• Yamoah K, Lal P, Awasthi S, Naghavi AO, Rounbehler RJ, Gerke T, Berglund AE, Pow-Sang JM, Schaeffer EM, Dhillon J, Park JY, Rebbeck TR. TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer. Prostate. 2021 Feb.81(2):109-117. Pubmedid: 33141952. Pmcid: PMC7810127.
• Siegel EM, Ajidahun A, Berglund A, Guerrero W, Eschrich S, Putney RM, Magliocco A, Riggs B, Winter K, Simko JP, Ajani JA, Guha C, Okawara GS, Abdalla I, Becker MJ, Pizzolato JF, Crane CH, Brown KD, Shibata D. Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS One. 2021 Dec.16(12):e0260857. Pubmedid: 34882728. Pmcid: PMC8659695.
• Wu Q, Berglund AE, MacAulay RJ, Etame AB. A Novel Role of BIRC3 in Stemness Reprogramming of Glioblastoma. Int J Mol Sci. 2021 Dec.23(1). Pubmedid: 35008722. Pmcid: PMC8745052.
• Berglund A, Matta J, Encarnación-Medina J, Ortiz-Sanchéz C, Dutil J, Linares R, Marcial J, Abreu-Takemura C, Moreno N, Putney R, Chakrabarti R, Lin HY, Yamoah K, Osterman CD, Wang L, Dhillon J, Kim Y, Kim SJ, Ruiz-Deya G, Park JY. Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men. Biomolecules. 2021 Dec.12(1). Pubmedid: 35053153. Pmcid: PMC8773891.
• Wu Q, Berglund AE, Etame AB. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma. Int J Mol Sci. 2021 Aug.22(15). Pubmedid: 34361090. Pmcid: PMC8347012.
• Falahat R, Berglund A, Putney RM, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, Barber GN, Mulé JJ. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc Natl Acad Sci U S A. 2021 Apr.118(15). Pubmedid: 33827917. Pmcid: PMC8053941.
• Lin HY, Huang PY, Cheng CH, Tung HY, Fang Z, Berglund AE, Chen A, French-Kwawu J, Harris D, Pow-Sang J, Yamoah K, Cleveland JL, Awasthi S, Rounbehler RJ, Gerke T, Dhillon J, Eeles R, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Neal DE, Nielsen SF, Nordestgaard BG, Gronberg H, Wiklund F, Giles GG, Haiman CA, Travis RC, Stanford JL, Kibel AS, Cybulski C, Khaw KT, Maier C, Thibodeau SN, Teixeira MR, Cannon-Albright L, Brenner H, Kaneva R, Pandha H, Srinivasan S, Clements J, Batra J, Park JY. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021 Apr.11(1):9264. Pubmedid: 33927218. Pmcid: PMC8084951.
• Hamaidi I, Zhang L, Kim N, Wang MH, Iclozan C, Fang B, Liu M, Koomen JM, Berglund AE, Yoder SJ, Yao J, Engelman RW, Creelan BC, Conejo-Garcia JR, Antonia SJ, Mulé JJ, Kim S. Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. Cell Metab. 2020 Sep.32(3):420-436.e12. Pubmedid: 32768387. Pmcid: PMC7484212.
• Berglund AE, Putney RM, Creed JH, Aden-Buie G, Gerke TA, Rounbehler RJ. Accessible Pipeline for Translational Research Using TCGA: Examples of Relating Gene Mechanism to Disease-Specific Outcomes. Methods Mol Biol. 2020 Sep.2194:127-142. Pubmedid: 32926365.
• Garg SK, Welsh EA, Fang B, Hernandez YI, Rose T, Gray J, Koomen JM, Berglund A, Mulé JJ, Markowitz J. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers (Basel). 2020 Nov.12(12). Pubmedid: 33255891. Pmcid: PMC7768436.
• Berglund A, Amankwah EK, Kim YC, Spiess PE, Sexton WJ, Manley B, Park HY, Wang L, Chahoud J, Chakrabarti R, Yeo CD, Luu HN, Pietro GD, Parker A, Park JY. Influence of gene expression on survival of clear cell renal cell carcinoma. Cancer Med. 2020 Nov.9(22):8662-8675. Pubmedid: 32986937. Pmcid: PMC7666730.
• Fowler EE, Berglund A, Schell MJ, Sellers TA, Eschrich S, Heine J. Empirically-derived synthetic populations to mitigate small sample sizes. J Biomed Inform. 2020 May.105:103408. Pubmedid: 32173502. Pmcid: PMC7839232.
• Jim HSL, Hoogland AI, Brownstein NC, Barata A, Dicker AP, Knoop H, Gonzalez BD, Perkins R, Rollison D, Gilbert SM, Nanda R, Berglund A, Mitchell R, Johnstone PAS. Innovations in research and clinical care using patient-generated health data. CA-Cancer J Clin. 2020 May.70(3):182-199. Pubmedid: 32311776. Pmcid: PMC7488179.
• Ganapathy K, Staklinski S, Hasan MF, Ottman R, Andl T, Berglund AE, Park JY, Chakrabarti R. Multifaceted Function of MicroRNA-299-3p Fosters an Antitumor Environment Through Modulation of Androgen Receptor and VEGFA Signaling Pathways in Prostate Cancer. Sci Rep. 2020 Mar.10(1):5167. Pubmedid: 32198489. Pmcid: PMC7083835.
• El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, Berglund A, Vishvakarma N, Ibrahim-Hashim A, Choi J, Luddy K, Gatenby R, Pilon-Thomas S, Anderson A, Ruffell B, Gillies R. Correction: Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Brit J Cancer. 2020 Mar.122(7):1118. Pubmedid: 31937927. Pmcid: PMC7109119.
• Creed JH, Berglund AE, Rounbehler RJ, Awasthi S, Cleveland JL, Park JY, Yamoah K, Gerke TA. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk. Cancer Epidemiol Biomarkers Prev. 2020 Jan.29(1):246-253. Pubmedid: 31757784. Pmcid: PMC7942810.
• Garg SK, Ott MJ, Mostofa AGM, Chen Z, Chen YA, Kroeger J, Cao B, Mailloux AW, Agrawal A, Schaible BJ, Sarnaik A, Weber JS, Berglund AE, Mulé JJ, Markowitz J. Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy. Front Immunol. 2020 Feb.11:164. Pubmedid: 32161584. Pmcid: PMC7052497.
• Berglund A, Mills M, Putney RM, Hamaidi I, Mulé J, Kim S. Methylation of immune synapse genes modulates tumor immunogenicity. J Clin Invest. 2020 Feb.130(2):974-980. Pubmedid: 31714899. Pmcid: PMC6994116.
• Bunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. Cancer Immunol Immun. 2020 Dec.69(12):2465-2476. Pubmedid: 32556443. Pmcid: PMC7680263.
• El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, Berglund A, Visvakarma N, Ibrahim-Hashim A, Choi J, Luddy K, Gatenby R, Pilon-Thomas S, Anderson A, Ruffell B, Gillies R. Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Brit J Cancer. 2019 Oct.121(7):556-566. Pubmedid: 31417189. Pmcid: PMC6889319.
• Wu Q, Berglund AE, Wang D, MacAulay RJ, Mulé JJ, Etame AB. Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma. Sci Rep. 2019 Oct.9(1):14072. Pubmedid: 31575897. Pmcid: PMC6773736.
• Boac BM, Abbasi F, Ismail-Khan R, Xiong Y, Siddique A, Park H, Han M, Saeed-Vafa D, Soliman H, Henry B, Pena MJ, McClung EC, Robertson SE, Todd SL, Lopez A, Sun W, Apuri S, Lancaster JM, Berglund AE, Magliocco AM, Marchion DC. Expression of the BAD pathway is a marker of triple-negative status and poor outcome. Sci Rep. 2019 Nov.9(1):17496. Pubmedid: 31767884. Pmcid: PMC6877530.
• Wikenius E, Moe V, Smith L, Heiervang ER, Berglund A. DNA methylation changes in infants between 6 and 52 weeks. Sci Rep. 2019 Nov.9(1):17587. Pubmedid: 31772264. Pmcid: PMC6879561.
• Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer P D. 2019 May.22(2):292-302. Pubmedid: 30367117. Pmcid: PMC6760558.
• Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, Pabón-Saldaña M, Darville L, Fang B, Rix U, Yoder S, Berglund A, Koomen JM, Haura EB, Abate-Daga D. An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal. 2019 Feb.12(568). Pubmedid: 30755478. Pmcid: PMC6506216.
• Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. J Urol. 2019 Aug.202(2):247-255. Pubmedid: 31107158. Pmcid: PMC7882398.
• Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Nov.27(11):1376-1383. Pubmedid: 30108099. Pmcid: PMC6214732.
• Zhu G, Nemoto S, Mailloux AW, Perez-Villarroel P, Nakagawa R, Falahat R, Berglund AE, Mulé JJ. Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol. 2018 Jul.9:1609. Pubmedid: 30061886. Pmcid: PMC6054958.
• Woods D, Ramakrishnan R, Laino AS, Berglund AE, Walton K, Betts BC, Weber JS. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma. Clin Cancer Res. 2018 Dec.24(24):6236-6247. Pubmedid: 30131384. Pmcid: PMC6295261.
• Ahmed KA, Scott JG, Arrington JA, Naghavi AO, Grass GD, Perez BA, Caudell JJ, Berglund AE, Welsh EA, Eschrich SA, Dilling TJ, Torres-Roca JF. Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. J Thorac Oncol. 2018 Aug.13(8):1121-1127. Pubmedid: 29733909. Pmcid: PMC7810135.
• Konno H, Yamauchi S, Berglund A, Putney RM, Mulé JJ, Barber GN. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene. 2018 Apr.37(15):2037-2051. Pubmedid: 29367762. Pmcid: PMC6029885.
• Teer JK, Zhang Y, Chen L, Welsh EA, Cress WD, Eschrich SA, Berglund AE. Evaluating somatic tumor mutation detection without matched normal samples. Hum Genomics. 2017 Sep.11(1):22. Pubmedid: 28870239. Pmcid: PMC5584341.
• Strom T, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, Fulp W, Thapa R, Coppola D, Kim S, Frakes J, Foekens J, Mulé JJ, Torres-Roca JF. Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer. 2017 Oct.84:304-314. Pubmedid: 28863385. Pmcid: PMC5822441.
• Luu HN, Lin HY, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park JY, Di Pietro G. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017 Mar.17(1):18. Pubmedid: 28320379. Pmcid: PMC5359825.
• Berglund AE, Welsh EA, Eschrich SA. Characteristics and Validation Techniques for PCA-Based Gene-Expression Signatures. Int J Genomics. 2017 Mar.2017:2354564. Pubmedid: 28265563. Pmcid: PMC5317117.
• Li B, Eschrich SA, Berglund A, Mitchell M, Fenstermacher D, Danaee H, Dai H, Sullivan D, Trepicchio WL, Dalton WS. Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility. JMIR Res Protoc. 2017 Mar.6(3):e45. Pubmedid: 28320689. Pmcid: PMC5379017.
• Prabhakaran S, Rizk VT, Ma Z, Cheng CH, Berglund AE, Coppola D, Khalil F, Mulé JJ, Soliman HH. Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. Breast Cancer Res. 2017 Jun.19(1):71. Pubmedid: 28629479. Pmcid: PMC5477261.
• Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017 Feb.18(2):202-211. Pubmedid: 27993569. Pmcid: PMC7771305.
• Wang D, Berglund AE, Kenchappa RS, MacAulay RJ, Mulé JJ, Etame AB. BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats. Sci Rep. 2017 Aug.7(1):9350. Pubmedid: 28839258. Pmcid: PMC5570925.
• Ahmed KA, Berglund AE, Welsh EA, Naghavi AO, Kim Y, Yu M, Robinson TJ, Eschrich SA, Johnstone PA, Torres-Roca JF. The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. Neurooncol. 2017 Aug.19(8):1145-1146. Pubmedid: 28379582. Pmcid: PMC5570253.
• Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster JM. Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Mol Clin Oncol. 2016 Mar.4(3):399-404. Pubmedid: 26998291. Pmcid: PMC4774474.
• Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ, Gray JE, Eschrich SA, Chen DT, Cress WD, Haura EB, Beg AA. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016 Jun.35(24):3209-3216. Pubmedid: 26477306. Pmcid: PMC4837098.
• Mårell L, Lindgren M, Nyhlin KT, Ahlgren C, Berglund A. "Struggle to obtain redress": Women's experiences of living with symptoms attributed to dental restorative materials and/or electromagnetic fields. Int J Qual Stud Health Well-being. 2016 Jan.11(1):32820. Pubmedid: 28169761.
• Wang D, Berglund A, Kenchappa RS, Forsyth PA, Mulé JJ, Etame AB. BIRC3 is a novel driver of therapeutic resistance in Glioblastoma. Sci Rep. 2016 Feb.6:21710. Pubmedid: 26888114. Pmcid: PMC4757860.
• Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Zgheib NB, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster JM. Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecol Oncol. 2016 Feb.140(2):259-263. Pubmedid: 26731723. Pmcid: PMC4724442.
• Berglund AE, Scott KE, Li W, Yang C, Fernandez MR, Schaub FX, Cleveland JL, Rounbehler RJ. Tristetraprolin disables prostate cancer maintenance by impairing proliferation and metabolic function. Oncotarget. 2016 Dec.7(50):83462-83475. Pubmedid: 27825143. Pmcid: PMC5341258.
• Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, Hoffe SE, Naghavi AO, Abuodeh YA, Frakes JM, Eschrich SA, Torres-Roca JF. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Aug.95(5):1399-1404. Pubmedid: 27319288. Pmcid: PMC7771381.
• Zargar-Shoshtari K, Spiess PE, Berglund AE, Sharma P, Powsang JM, Giuliano A, Magliocco AM, Dhillon J. Clinical Significance of p53 and p16(ink4a) Status in a Contemporary North American Penile Carcinoma Cohort. Clin Genitourin Cancer. 2016 Aug.14(4):346-351. Pubmedid: 26794389. Pmcid: PMC7771549.
• Wang H, Schabath MB, Liu Y, Berglund AE, Bloom GC, Kim J, Stringfield O, Eikman EA, Klippenstein DL, Heine JJ, Eschrich SA, Ye Z, Gillies RJ. Semiquantitative Computed Tomography Characteristics for Lung Adenocarcinoma and Their Association With Lung Cancer Survival. Clin Lung Cancer. 2015 Nov.16(6):e141-e163. Pubmedid: 26077095. Pmcid: PMC4609593.
• Grove O, Berglund AE, Schabath MB, Aerts HJ, Dekker A, Wang H, Velazquez ER, Lambin P, Gu Y, Balagurunathan Y, Eikman E, Gatenby RA, Eschrich S, Gillies RJ. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS One. 2015 Mar.10(3):e0118261. Pubmedid: 25739030. Pmcid: PMC4349806.
• Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, Shridhar R, Torres-Roca JF. Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. Int J Radiat Oncol Biol Phys. 2015 Jul.92(4):837-842. Pubmedid: 25838188. Pmcid: PMC4481172.
• Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster JM. BAD-mediated apoptotic pathway is associated with human cancer development. Int J Mol Med. 2015 Apr.35(4):1081-1087. Pubmedid: 25653146. Pmcid: PMC4356438.
• Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol. 2014 Oct.48(5):426-435. Pubmedid: 24611795.
• Berglund A, Ekelund M, Fletcher MA, Nyman L. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction. plos one. 2014 nov.9(11):e112211. pubmedid:>25379659. Pmcid: PMC4224441.
• Siegel EM, Berglund AE, Riggs BM, Eschrich SA, Putney RM, Ajidahun AO, Coppola D, Shibata D. Expanding epigenomics to archived FFPE tissues: an evaluation of DNA repair methodologies. Cancer Epidemiol Biomarkers Prev. 2014 Dec.23(12):2622-2631. Pubmedid: 25472669. Pmcid: PMC4256717.
• Enlund M, Berglund A, Andreasson K, Cicek C, Enlund A, Bergkvist L. The choice of anaesthetic--sevoflurane or propofol--and outcome from cancer surgery: a retrospective analysis. Ups J Med Sci. 2014 Aug.119(3):251-261. Pubmedid: 24857018. Pmcid: PMC4116765.
• Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Moughan J, Ajani J, Magliocco A, Elahi A, Hoffe S, Shibata D. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014 Aug.57(8):941-957. Pubmedid: 25003289. Pmcid: PMC4100249.
• Lundh MH, Lampic C, Nordin K, Ahlgren J, Bergkvist L, Lambe M, Berglund A, Johansson B. Changes in health-related quality of life by occupational status among women diagnosed with breast cancer--a population-based cohort study. Psychooncology. 2013 Oct.22(10):2321-2331. Pubmedid: 23585294.
• Siegel E, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Ajani J, Magliocco A, Elahi A, Coppola D, Shibata D. Epigenomic profiling of anal cancer: does size matter? An RTOG 98-11 specimen study. Sex Health. 2013 Nov.10(6):590. Pubmedid: 24262262.
• Marchion DC, Bicaku E, Xiong Y, Zgheib NB, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May.29(5):2011-2018. Pubmedid: 23467907. Pmcid: PMC4536335.
• Hernandez JM, Siegel EM, Riggs B, Eschrich S, Elahi A, Qu X, Ajidahun A, Berglund A, Coppola D, Grady WM, Giuliano AR, Shibata D. DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia. PLoS One. 2013 May.7(11):e50533. Pubmedid: 23226306. Pmcid: PMC3511539.
• Welsh EA, Eschrich SA, Berglund AE, Fenstermacher DA. Iterative rank-order normalization of gene expression microarray data. BMC Bioinformatics. 2013 May.14:153. Pubmedid: 23647742. Pmcid: PMC3651355.
• Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. Sci Rep. 2013 Mar.2:765. Pubmedid: 23097687. Pmcid: PMC3479449.
• Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, König A, Fernandes O, Karlsson M, Helenius G, Karlsson C, Rahnenführer J, Hengstler JG, Micke P. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2013 Jan.19(1):194-204. Pubmedid: 23032747.
• Marchion DC, Xiong Y, Chon HS, Sawah EA, Zgheib NB, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM. Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. Am J Obstet Gynecol. 2013 Dec.209(6):576.e1-576.e16. Pubmedid: 23933223. Pmcid: PMC3840156.
• Berglund A, Lambe M, Lüchtenborg M, Linklater K, Peake MD, Holmberg L, Møller H. Social differences in lung cancer management and survival in South East England: a cohort study. BMJ Open. 2012 Oct.2(3). Pubmedid: 22637374. Pmcid: PMC3367157.
• Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, Forster K, Aerts HJ, Dekker A, Fenstermacher D, Goldgof DB, Hall LO, Lambin P, Balagurunathan Y, Gatenby RA, Gillies RJ. Radiomics: the process and the challenges. Magn Reson Imaging. 2012 Nov.30(9):1234-1248. Pubmedid: 22898692. Pmcid: PMC3563280.
• Edlund K, Lindskog C, Saito A, Berglund A, Pontén F, Göransson-Kultima H, Isaksson A, Jirström K, Planck M, Johansson L, Lambe M, Holmberg L, Nyberg F, Ekman S, Bergqvist M, Landelius P, Lamberg K, Botling J, Ostman A, Micke P. CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int J Cancer. 2012 Nov.131(10):2264-2273. Pubmedid: 22392539.
• Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res. 2012 May.18(9):2695-2703. Pubmedid: 22351685.
• Källestedt ML, Berglund A, Herlitz J, Leppert J, Enlund M. The impact of CPR and AED training on healthcare professionals' self-perceived attitudes to performing resuscitation. Scand J Trauma Resusc Emerg Med. 2012 Apr.20:26. Pubmedid: 22480164. Pmcid: PMC3352321.
• Stenberg P, Pettersson F, Saura AO, Berglund A, Larsson J. Sequence signature analysis of chromosome identity in three Drosophila species. BMC Bioinformatics. 2005 Jun.6:158. Pubmedid: 15975141. Pmcid: PMC1181806.
• Schrader J, Nilsson J, Mellerowicz E, Berglund A, Nilsson P, Hertzberg M, Sandberg G. A high-resolution transcript profile across the wood-forming meristem of poplar identifies potential regulators of cambial stem cell identity. Plant Cell. 2004 Sep.16(9):2278-2292. Pubmedid: 15316113. Pmcid: PMC520933.
• van Noort R, Gjerdet NR, Schedle A, Björkman L, Berglund A. An overview of the current status of national reporting systems for adverse reactions to dental materials. J Dent. 2004 Jul.32(5):351-358. Pubmedid: 15193782.
• Wissel K, Pettersson F, Berglund A, Jansson S. What affects mRNA levels in leaves of field-grown aspen? A study of developmental and environmental influences. Plant Physiol. 2003 Nov.133(3):1190-1197. Pubmedid: 14563929. Pmcid: PMC281614.

• Title: Epigenetic Changes in Cervical Cancer Driving Immune Evasion, Progression, and Aging
  Sponsor: Moffitt Cancer Center
  PI (Contact): Ahmed, K., CO-PI: Berglund, A.
• Title: Deconvolute Key Biological Drivers That Define Subsets of Lethal Prostate Cancer in African American Men
  Sponsor: US Army
  PI: Berglund, A.
• Title: Epigenetic Regulation of the Immune Synapse in Melanoma
  Sponsor: US Army
  PI: Berglund, A.